Roche’s Master Plan: Perjeta Gains Early Breast Cancer Approval, Late-Stage Kadcyla Data
This article was originally published in The Pink Sheet Daily
Perjeta’s approval in neoadjuvant breast cancer signals paradigm change as first approval under new pathway. Meanwhile, antibody-drug conjugate Kadcyla proves its worth in heavily pretreated, advanced breast cancer.
You may also be interested in...
KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.
Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.
More work needs to be done to validate MRD as predictive of clinical outcomes in hematological malignancies before it can be used as the basis for accelerated approval, FDA and other stakeholders say.